ACTAZE

Brand name authorized in: Australia

Active ingredients

The drug ACTAZE contains one active pharmaceutical ingredient (API):

1 Pioglitazone
UNII X4OV71U42S - PIOGLITAZONE

Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.

Read about Pioglitazone

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code
Group title
Classification
Pioglitazone
A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BG Thiazolidinediones
Discover more medicines within A10BG03

Unique identifiers

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country
Identification scheme
Identifier(s)
AU
Pharmaceutical Benefits Scheme
Identifier(s): 8694N, 8695P, 8696Q